Drug Interactions between Dexacort Phosphate in Turbinaire and esketamine
This report displays the potential drug interactions for the following 2 drugs:
- Dexacort Phosphate in Turbinaire (dexamethasone nasal)
- esketamine
Interactions between your drugs
dexAMETHasone nasal esketamine
Applies to: Dexacort Phosphate in Turbinaire (dexamethasone nasal) and esketamine
ADJUST DOSING INTERVAL: Data are limited with respect to any potential interaction between intranasal esketamine and other nasal products during concomitant administration. In pharmacokinetic studies, mometasone furoate and oxymetazoline hydrochloride administered intranasally one hour before esketamine demonstrated no clinically significant effects on esketamine peak plasma concentration and exposure.
MANAGEMENT: To minimize the risk of interaction, patients who require a nasal corticosteroid or nasal decongestant on a day when esketamine dosing is scheduled should administer these medications at least one hour before esketamine.
References (2)
- Cerner Multum, Inc. "Australian Product Information."
- (2019) "Product Information. Spravato (esketamine)." Janssen Pharmaceuticals
Drug and food interactions
esketamine food
Applies to: esketamine
GENERALLY AVOID: Concomitant use of esketamine with central nervous system (CNS) depressants such as alcohol may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.
ADJUST DOSING INTERVAL: Nausea and vomiting may occur following intranasal administration of esketamine. In clinical studies, nausea and vomiting were reported in approximately 25% and 10% of esketamine-treated patients, respectively.
MANAGEMENT: Patients receiving esketamine should be advised to avoid or limit the consumption of alcohol. In addition, to help prevent nausea and vomiting, patients should be advised not to eat for at least 2 hours before intranasal administration of esketamine and not to drink liquids for at least 30 minutes prior to administration.
References (2)
- Cerner Multum, Inc. "Australian Product Information."
- (2019) "Product Information. Spravato (esketamine)." Janssen Pharmaceuticals
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.